Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vemurafenib

FDA-approved product (tablet, oral), marketed as Zelboraf.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vemurafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vemurafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vemurafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    NCT06692491 · start 2025-01-01

    Registered record
    Registry ID
    NCT06692491
    Conditions
    Rare Tumour
    Interventions
    Albumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine; Cisplatin; Irinotecan; Fluorouracil; Nivolumab; Pembrolizumab; Durvalumab; Atezolizumab; Sintilimab; Tislelizumab; Camrelizumab; Toripalimab; Serplulimab; Adebrelimab; Envafolimab; Osimertinib; Alectinib; Vemurafenib; Pamiparib; Pyrotinib; Imatinib; Palbociclib; Savolitinib; Entrectinib; Other
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2029-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Tumour
    InterventionAlbumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine +24 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    NCT06008119 · start 2023-10-25

    Registered record
    Registry ID
    NCT06008119
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    Tunlametinib plus Vemurafenib; Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-25
    Completion
    2026-12-24
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    InterventionTunlametinib plus Vemurafenib; Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
    PhasePhase 3
    Registry statusRecruiting

  • KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

    NCT05525858 · start 2022-09-28

    Registered record
    Registry ID
    NCT05525858
    Conditions
    Solid Tumor; Advanced Solid Tumor; Metastatic Cancer
    Interventions
    Alectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab; Trastuzumab emtansine; Vemurafenib; Bevacizumab + Erlotinib; Entrectinib; Pralsetinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-28
    Completion
    2027-03
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Advanced Solid Tumor; Metastatic Cancer
    InterventionAlectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab +5 more
    PhaseNot recorded
    Registry statusRecruiting

  • Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

    NCT05233332 · start 2022-02-24

    Registered record
    Registry ID
    NCT05233332
    Conditions
    CRC
    Interventions
    HL-085; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-02-24
    Completion
    2024-07-20
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCRC
    InterventionHL-085; Vemurafenib
    PhasePhase 2
    Registry statusUnknown

  • a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

    NCT05177666 · start 2021-12-30

    Registered record
    Registry ID
    NCT05177666
    Conditions
    Feasibility; Effectiveness; Safety; Targeted Molecular Therapy
    Interventions
    Targeted therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-30
    Completion
    2024-03-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFeasibility; Effectiveness; Safety; Targeted Molecular Therapy
    InterventionTargeted therapy
    PhaseNot recorded
    Registry statusUnknown

  • CRAFT: The NCT-PMO-1602 Phase II Trial

    NCT04551521 · start 2021-10-13

    Registered record
    Registry ID
    NCT04551521
    Conditions
    Metastatic or Locally Advanced Malignancies
    Interventions
    Vemurafenib; Cobimetinib; Atezolizumab; Trastuzumab; Pertuzumab; Alectinib; Ipatasertib; Atezolizumab; Atezolizumab; Atezolizumab; Inavolisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-10-13
    Completion
    2024-12-30
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic or Locally Advanced Malignancies
    InterventionVemurafenib; Cobimetinib; Atezolizumab; Trastuzumab +7 more
    PhasePhase 2
    Registry statusCompleted

  • Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    NCT05019534 · start 2021-08-15

    Registered record
    Registry ID
    NCT05019534
    Conditions
    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
    Interventions
    Vemurafenib Oral Tablet [Zelboraf]; Cetuximab Injection [Erbitux]; Camrelizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2022-12-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
    InterventionVemurafenib Oral Tablet [Zelboraf]; Cetuximab Injection [Erbitux]; Camrelizumab
    PhasePhase 1
    Registry statusUnknown

  • Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

    NCT03430947 · start 2018-07-01

    Registered record
    Registry ID
    NCT03430947
    Conditions
    Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases
    Interventions
    Vemurafenib; Cobimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-07-01
    Completion
    2023-02-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases
    InterventionVemurafenib; Cobimetinib
    PhasePhase 2
    Registry statusTerminated

  • VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

    NCT05540951 · start 2018-06-01

    Registered record
    Registry ID
    NCT05540951
    Conditions
    Colorectal Cancer
    Interventions
    VIC; Bevacizumab Plus Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-06-01
    Completion
    2022-12-30
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionVIC; Bevacizumab Plus Chemotherapy
    PhasePhase 3
    Registry statusUnknown

  • Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

    NCT03224208 · start 2018-05-17

    Registered record
    Registry ID
    NCT03224208
    Conditions
    Melanoma; Melanoma (Skin); Melanoma Stage
    Interventions
    Vemurafenib; Cobimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-05-17
    Completion
    2021-01-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Melanoma (Skin); Melanoma Stage
    InterventionVemurafenib; Cobimetinib
    PhasePhase 2
    Registry statusTerminated

  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    NCT03155620 · start 2017-07-31

    Registered record
    Registry ID
    NCT03155620
    Conditions
    Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphom
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Ensartinib; Erdafitinib; Ivosidenib; Laboratory Biomarker Analysis; Larotrectinib Sulfate; Magnetic Resonance Imaging; Mutation Carrier Screening; Olaparib; Palbociclib; Pharmacological Study; Positron Emission Tomography; Radionuclide Imaging; Samotolisib; Selpercatinib; Selumetinib Sulfate; Tazemetostat; Tipifarnib; Ulixertinib; Vemurafenib; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-07-31
    Completion
    2027-01-06
    Enrolment
    1,377

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma +28 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan +21 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

    NCT03181100 · start 2017-07-27

    Registered record
    Registry ID
    NCT03181100
    Conditions
    Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Carcinoma
    Interventions
    Atezolizumab; Bevacizumab; Cobimetinib; Nab-paclitaxel; Paclitaxel; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-07-27
    Completion
    2027-07-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 +3 more
    InterventionAtezolizumab; Bevacizumab; Cobimetinib; Nab-paclitaxel +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

    NCT02968303 · start 2017-01-27

    Registered record
    Registry ID
    NCT02968303
    Conditions
    Melanoma, Malignant, of Soft Parts
    Interventions
    Vemurafenib and Cobimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-01-27
    Completion
    2023-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma, Malignant, of Soft Parts
    InterventionVemurafenib and Cobimetinib
    PhasePhase 2
    Registry statusUnknown

  • PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

    NCT03013491 · start 2017-01-19

    Registered record
    Registry ID
    NCT03013491
    Conditions
    Solid Tumor; Lymphoma
    Interventions
    CX-072; ipilimumab; vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-01-19
    Completion
    2020-10-27
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Lymphoma
    InterventionCX-072; ipilimumab; vemurafenib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

    NCT02902029 · start 2016-11

    Registered record
    Registry ID
    NCT02902029
    Conditions
    Malignant Melanoma
    Interventions
    Vemurafenib; Cobimetinib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11
    Completion
    2024-03
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma
    InterventionVemurafenib; Cobimetinib; Atezolizumab
    PhasePhase 2
    Registry statusCompleted